baber/WOPTO huggingface dataset:
Patent NZ-549942-A (NZ)
Title: Process and plant for conversion of waste material to liquid fuel
Inventor: BAKER GARRY
IPC: C10G11/02
Filed: 2005-03-11
Abstract: A process and plant for the thermocatalytic conversion of waste materials into reusable fuels and a fuel produced by the process, involving the steps of delivering melted waste material (11) to one or more pyrolysis chambers (26) via heated and valved manifolds (22) and effecting pyrolysis of the waste material into a gaseous state in an oxygen purged and pressure controlled environment. Pyrolytic gases are then transferred to a catalytic converter (29) where the molecular structure of the gaseous material is altered in structure and form, with gases then transferred to one or more condensers (30a) to distil and cool gases in to their respective fractions. After post pyrolysis treatment, fuel fractions thon form a useable fuel. Includes the melting of waste (plastic) material (11) before delivery into any of the pyrolysis chambers (26), making the movement of material into the catalytic tower (29) a semi-continuous operation, directing melted waste material into one or more, but preferably four, pyrolysis chambers (26), making each chamber capable of independent operation, optionally mechanically removing waste char from the pyrolysis chamber by use of an auger or other suitable means.
Patent NZ-555696-A (NZ)
Title: Defoamer oil-in-water emulsion comprising hydrophobic particles of ethylene bis stearamide
Inventor: CHENG HUAI N
IPC: C07C233/01
Filed: 2005-12-08
Abstract: Disclosed is an oil-in-water emulsion which is used to control foam, comprising a) an oil blend comprising; silicone and at least one triglyceride oil; b) a stabilising agent comprising a phospholipid; c) hydrophobic particles; d) non-ionic surfactants and dispersant; and wherein the hydrophobic particles are selected from the group consisting of ethylene bistearamide and hydrophobic silica, wherein water comprises at least 51% by weight of the total emulsion, wherein the silicone content is greater than 2.5% by weight of the total weight of the emulsion and wherein the oil blend, the stabilising agent and the surfactants and dispersants all have flash points of 140°F (60°C) or higher. Also disclosed is a method of controlling foam in pulp and paper making systems comprising adding to a pulp and papermaking system a composition comprising: a) an oil blend comprising silicone and at least one triglyceride oil; b) a stabilising agent; c.) hydrophobic particles; d) surfactants and/or dispersants, and wherein the silicone content is greater than 2.5% by weight of the total weight of the emulsion and wherein the oil blend, stabilising agent, surfactants and dispersants have flash points of 140°F (60°C) or higher.
Patent NZ-560513-A (NZ)
Title: Indole compound and use thereof
Inventor: TAKEUCHI JUN
IPC: A61K31/427
Filed: 2006-02-24
Abstract: Indole compounds represented by the general formula (Ia1), salts or solvates thereof are disclosed, wherein the variables are as defined in the specification. These compounds have a leukotriene receptor antagonistic effect which is expected to be more effective than those of the leulotriene receptor antagonists currently used in clinical medicine and, therefore, is useful as an agent for prevention and/or treatment of a leukotriene-mediated disease such as a respiratory disease (e.g., bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g., interstitial pneumonia), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g., acute sinusitis, chronic sinusitis) or the like, an expectorant and an antitussive comprising these compounds are also disclosed.
Patent NZ-580245-A (NZ)
Title: Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
Inventor: BURKLY LINDA C
IPC: C12N15/13
Filed: 2008-03-21
Abstract: An anti-CD154 antibody that comprises the heavy chain CDR1, CDR2 and CDR3 sequence SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 respectively and the light chain CDR1, CDR2 and CDR3 sequences SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 respectively. Also disclosed are methods of the production of the antibody and uses thereof for treating rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, inflammatory bowel disease, Crohn's disease, psoriasis, scleroderma and multiple sclerosis.
Patent NZ-582616-A (NZ)
Title: Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
Inventor: KOPEN GENE
IPC: C12N5/077
Filed: 2008-06-16
Abstract: Disclosed is the use of an isolated population of bone marrow-derived self-renewing colony-forming somatic cells (CF-SC) in the manufacture of a medicament to stimulate or enhance angiogenesis, wherein said CF-SC do not have multipotent differentiation capacity, wherein said CF-SC have a normal karyotype, wherein said CF-SC are non-immortalized, wherein said CF-SC express CD13, CD44, CD49c, CD90, HLA Class-1 and â (beta) 2-Microglobulin, and wherein said CF-SC do not express CD10, CD34, CD45, CD62L, or CD106. Further disclosed is a composition suitable for stimulating or enhancing angiogenesis comprising a pharmaceutically acceptable mixture of purified naturally occurring or isolated recombinant extracellular matrix or blood plasma proteins and bone marrow-derived self-renewing colony-forming somatic cells (CF-SC), wherein said CF-SC have a normal karyotype, wherein said CF-SC are non-immortalized, wherein said CF-SC express CD13, CD44, CD49c, CD90, HLA Class-1 and â (beta) 2-Microglobulin, and wherein said CF-SC do not express CD10, CD34, CD45, CD62L, or CD106.
Patent NZ-584387-A (NZ)
Title: Novel imidazole derivatives
Inventor: DUMEUNIER RAPHAEL
IPC: A61P35/00
Filed: 2008-10-24
Abstract: Disclosed herein is an imidazole derivative of formula (I), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds. Such compounds have micorbiocidal activity, in particular fungicidal activity and are useful in controlling or preventing infestation of plants, harvested food crops, sees or non-living materials by phytopathogenic microorganisms.
Patent NZ-588601-A (NZ)
Title: Low viscosity mono-unsaturated acid-containing vegetable oil-based dielectric fluids
Inventor: AMANULLAH MOHAMMED
IPC: H01B3/20
Filed: 2006-10-11
Abstract: Disclosed is a dielectric fluid composition which comprises: a) 40%-60% v/v of a vegetable oil comprising a mono-unsaturated fatty acid component; and b) 40%-60% v/v of a viscosity modifier which comprises one or more fatty acid alkyl esters; wherein said vegetable oil component and said viscosity modifier have above 60% of the fatty acid moieties being derived from one or more mono-unsaturated fatty acids, and wherein the alkyl moiety of the fatty acid alkyl esters of the viscosity modifier has from 1 to 4 carbon atoms. Further disclosed is a transformer having a housing which accommodates a transformer core/coil assembly and a dielectric fluid composition surrounding said core/coil assembly, wherein the dielectric fluid composition is as defined above.
Patent NZ-588897-A (NZ)
Title: A field emission system and method
Inventor: FULLERTON LARRY W
IPC: G06K7/08
Filed: 2009-03-31
Abstract: 588897 Disclosed is a field emission system (2014) including a first field emission structure (2020) and a second field emission structure (2016). The first (2020) and second (2016) field emission structures each include an array of field emission sources (2008) each having positions and polarities relating to a desired spatial force function. The force function corresponds to different spatial forces produced by different spatial alignments of the first (2020) and second (2016) field emission structures within a field domain. The spatial force function is in accordance with a code modulo of a code, such that the code modulo has a length equal to the length of the code. The code modulo defines one peak spatial force corresponding to a first relative alignment of the first (2020) and second (2016) field emission structures and an off peak spatial force corresponding to a second relative alignment of the first (2020) and second (2016) field emission structures. The off peak spatial force is results from cancellation of at least one attractive force by at least one repellent force between the first (2020) and second (2016) field emission structures.
Patent NZ-588962-A (NZ)
Title: Link coupling for towing wheeli bins
Inventor: BRADSHAW MARK TODD
IPC: B60D1/04
Filed: 2010-11-02
Abstract: A wheeli-bin coupler is rigid and has an upper portion 32 to engage over the rim of a wheeli-bin 20 opposite the handle and a lower portion 38 to engage the handles of an adjacent bin to connect the bins together and allow the bins to be wheeled along in tandem.
Patent NZ-594051-A (NZ)
Title: Spring compactor machine
Inventor: TAYLOR CECIL RAY
IPC: B30B5/00
Filed: 2010-02-09
Abstract: 594051 Disclosed is a compression spring compactor machine, for compacting a mattress or sitting furniture for recycling or disposal. The separate compression spring is to be compacted being at rest when x = 0 and the restoring force, F = 0, in Hooke's law spring equation. The spring compactor machine comprises at least one movable ram to apply a force to the compression spring at an angle substantially between 35 degrees and 155 degrees to an at rest compression spring's restoring force axis with an equal and opposite restraining force applied substantially between 215 and 325 degrees to the at rest compression spring's restoring force axis. When in combination, both the applied force and the restraining force substantially exceed the plastic limit of the compression spring, the compression spring deforms into a compacted compression spring and the restoring force of the compression spring no longer returns the spring to its original shape. At least one compaction chamber includes at least one moveable ram to exert an applied force to the compression spring and at least one resistance block to provide the restraining force to the compression spring. A device applies an upward force and a downward force along or substantially parallel to the spring's restoring force axis aiding in holding the compression spring in its desired compaction position during the compaction operation.
Patent NZ-595253-A (NZ)
Title: Anti-slip stocking sole with grip members on the bottom surface comprising rough tread
Inventor: BURMEISTER DIANNE
IPC: A61F13/08
Filed: 2010-11-01
Abstract: Disclosed is a compression stocking with a foot portion for covering at least portion of a wearer's foot. The foot portion includes a toe region and a heel region and a sole extending between the toe region and heel region, the sole having a bottom surface for contacting a floor. Anti-slip means are provided at the bottom surface of the sole, the anti-slip means comprising a tread that overlays at least a portion of the bottom surface, the tread having a rougher surface than the surrounding surfaces of the foot portion.
Patent NZ-595583-A (NZ)
Title: Improved Infant Wrap For Restraining The Movement Of An Infant On A Mattress or Cot
Inventor: VAN GISBERGEN-RUTHERFORD MIRIAM PETRONELLA
IPC: A47D13/08
Filed: 2011-10-05
Abstract: Disclosed is a wrap for restraining an infant, a baby or a child on a mattress. It includes base member (3) for attaching to a mattress and a securing member (1) sufficiently long to encircle an infant's torso. The securing member is fixed to the base member at a location intermediate along a length of the base member and intermediate along a length of the securing member. It includes a first releasable fastener portion (6) on a first free end of the securing member (5) and a second releasable fastener portion (6) on a second free end of the securing member (5). The second releasable fastener portion is engageable with the first releasable fastener portion by overlapping the respective end. The wrap further includes a hampering member which in use covers at least one of the overlapped ends of the securing member to prevent the fastener portions from being disengaged.
Patent NZ-596431-A (NZ)
Title: Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
Inventor: TREPPENDAHL SVEND
IPC: A61K31/495
Filed: 2010-04-16
Abstract: The compound 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (compound I) has been disclosed in WO 03/029232 as the free base. The present disclosure is directed to the finding that the L-lactic acid addition salt (=L-lactate), the D-lactic acid addition salt (=D-lactate) and the DL-lactic acid addition salt (=DL-lactate) of 1-[2-(2,4dimethylphenylsulfanyl)phenyl]piperazine are highly soluble whereas the usefulness of other known forms is compromised by poor solubility.
Patent NZ-598232-A (NZ)
Title: Substituted benzamide derivatives as glucokinase (gk) activators
Inventor: JAIN MUKUL R
IPC: A61K31/427
Filed: 2010-07-22
Abstract: The present invention relates to substituted benzamide derivatives of the general Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites, and polymorphs and can be useful for treating disease states mediated by glucokinase. Compounds disclosed herein can be used for reducing blood glucose levels and for increasing insulin secretion for treating type II diabetes. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds, and their use.
Patent NZ-599033-A (NZ)
Title: A process for purifying staurosporine by seeding
Inventor: HOEHN PASCALE
IPC: C07D498/22
Filed: 2005-11-03
Abstract: Disclosed herein is process for purifying staurosporine comprising: a) Providing a solution of staurosporine in a first solvent, wherein the first solvent is selected from benzyl alcohol, DMF, DMSO, acetic acid and PEG; b) Seeding the solution with purified staurosporine in a second solvent, wherein the second solvent is selected from ethanol, THF, and a solution of ethanol in water; and c) Isolating the product. Also disclosed is a process for the preparation of N-benzoyl-staurosporine comprising: a) Reacting staurosporine with benzoic anhydride to form a solution; b) Seeding the solution with amorphous N-benzoyl-staurosporine; and c) Isolating the product.
Patent NZ-599753-A (NZ)
Title: Led apparatus and method for accurate lens alignment
Inventor: WILCOX KURT S
IPC: F21S8/00
Filed: 2010-10-26
Abstract: An LED apparatus 10A comprising a mounting board 30 having an LED-supporting surface 31 with at least one LED 11 on it, the LED 11 defining a light-emission axis, at least one lens 20 corresponding to the LED 11 establishing a light path therebetween, a lens-aligner 40 having front and back surfaces with the lens 11 being on the front surface, the lens-aligner 40 being between the mounting board 30 and the lens 11. The apparatus has a first and second alignment features, with one 34 in the mounting board 30 and the other 44 in the lens-aligner 40. The alignment features align the lens 20 over the corresponding LED 11 thereby establishing a light path therebetween.
Patent NZ-601029-A (NZ)
Title: Flavor-enriching agent
Inventor: MIYAKI TAKASHI
IPC: A23L27/10
Filed: 2010-12-28
Abstract: 601029 Disclosed is a method for imparting kokumi to a food or beverage composition comprising adding γ-Glu-Nva to said composition. Further disclosed is a food composition comprising γ-Glu-Nva in an amount ranging from 0.1 ppb to 99.9% by mass.
Patent NZ-601408-A (NZ)
Title: Novel 3-hydroxy-5-arylisothiazole derivative
Inventor: MAKABE MUNEYOSHI
IPC: A61K31/425
Filed: 2010-12-24
Abstract: 601408 Disclosed are 5-aryl-isothiazol-3-ol 1-oxide derivatives / 1-oxo-5-aryl-isothiazolidin-3-one derivatives as represented by the general formula (I), where n is an integer of 1; p is an integer of 0 to 4; j is an integer 5 of 0 to 3; k is an integer of 0 to 2; ring A is a C6-14 aryl group which is optionally substituted with 1 to 5 L(s) or a 3- to 14-membered heterocyclic group which is optionally substituted with 1 to 5 L(s); ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is an oxygen atom, a sulfur atom, or -NR7-; and wherein the remaining substituents are as defined herein. Representative compounds include 5-(4-((3-(2,6-dimethyl-4-(2-ethoxyethoxy)phenyl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(2,4-dimethyl-6-(3-hydroxy-3-methylbutoxy)pyridin-3-yl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(2,6-dimethyl-3-fluoro-4-(3-(2-oxopyrrolidin-1-yl)propoxy)phenyl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(2,6-dimethyl-3-fluoro-4-((3-methyl-3-oxetanyl)methoxy)phenyl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)phenyl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(2,6-dimethyl-4-(3-hydroxypropoxy)phenyl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(2,4-dimethyl-6-(3-hydroxypropoxy)pyridin-3-yl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(4-((2R)-2,3-dihydroxypropoxy)-2,6-dimethyl-3-fluorophenyl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; 5-(4-((3-(2,6-dimethyl-4-((3R)-3-hydroxybutoxy)phenyl)phenyl)methoxy)phenyl)isothiazol-3-ol 1-oxide; N-[3-[4-[3-[[4-(3-hydroxy-1-oxo-isothiazol-5-yl)phenoxy]methyl]phenyl]-3,5-dimethylphenoxy]propyl]methanesulfonamide; 5-[4-[[3-[4-(3-aminopropoxy)-2,6-dimethylphenyl]phenyl]methoxy]phenyl]isothiazol-3-ol 1-oxide; 5-[4-[[(1R)-4-(6-methoxy-2-methylpyridin-3-yl)-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]isothiazol-3-ol 1-oxide trifluoroacetate salt; 5-[4-[[(1R)-4-[6-(3-hydroxy-3-methylbutoxy)-2-methylpyridin-3-yl]-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]isothiazol-3-ol 1-oxide; 5-[4-[[(1R)-4-[6-(2-ethoxyethoxy)-2-methylpyridin-3-yl]-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]isothiazol-3-ol 1-oxide; and 5-[4-[[(1R)-4-[4-(3-hydroxy-3-methylbutoxy)-2,6-dimethylphenyl]-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]isothiazol-3-ol 1-oxide. Further disclosed is a pharmaceutical composition comprising a compound as defined above, pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable solvate of the compound or a pharmaceutically acceptable solvate of the salt and optionally a DPP-IV inhibitor such as sitagliptin, vildagliptin, alogliptin, saxagliptin, linagliptin, and teneligliptin for treating or preventing diabetes.
Patent NZ-616359-A (NZ)
Title: Drug delivery device and cartridge holder for a drug delivery device
Inventor: SCHNEIDER CHRISTIANE
IPC: A61M5/31
Filed: 2012-05-04
Abstract: A coupling arrangement for a cartridge holder of drug delivery device. A drug delivery device is provided comprising a cartridge holder (2) comprising at least one guide track, and a body comprising at least one interaction member. The interaction member is adapted to mechanically cooperate with the at least one guide track. The guide track comprises a first section (12A) and a second section (12B). The path which is defined by the first section (12A) encloses an angle with the longitudinal axis of the device, wherein the second section (12B) encloses an angle with the longitudinal axis of the device which is great than that of the first section. The interaction member is configured to mechanically cooperate with the first section (12A) such that the cartridge holder (2) is axially moved and rotated with respect to the body. The interaction member is configured to mechanically cooperate with the second section (12B) such that the cartridge holder (2) is rotated with respect to the body, whereby an axial movement of the cartridge holder (2) with respect to the body is substantially prevented.
Patent NZ-616691-A (NZ)
Title: High-frequency electrical nerve block
Inventor: FANG ZI-PING
IPC: A61N1/36
Filed: 2012-05-18
Abstract: A device for ameliorating sensory nerve pain in a patient in need thereof, the device comprising: an implanted electrode (50) and a waveform generator (10). The implanted electrode (50) contacts a trunk of a sensory peripheral nerve in the patient at a plurality of contact surfaces with the nerve trunk. The waveform generator (10) is operatively connected to the implanted electrode for generating a waveform at one of a voltage ranging from 4 Volt peak-to-peak (Vpp) to 20 Vpp, or a current ranging from 4 milli-Amp peak-to-peak (mApp) to 26 mApp.
Patent NZ-630888-A (NZ)
Title: Antibody drug conjugate (adc) purification
Inventor: CALVIN LAWRENCE BECKER
IPC: C07K16/28
Filed: 2014-03-14
Abstract: Discloses pharmaceutical compositions comprising antibody drug conjugates of an anti-EGFR antibody with the CDR sequences of SEQ ID NO: 2-4 and 7-9 and an auristatin sucj as monomethylauristatine E (MMAE) or monomethylauristatine F (MMAF) and wherein 70% of ADCs have a drug loading of 4 species or less. Further discloses linkers including valine-citruline (vc) linkers and malemidocaproyl (mc) linkers.
Patent NZ-702715-A (NZ)
Title: Pyrimidinyl tyrosine kinase inhibitors
Inventor: HOPKINS BRIAN T
IPC: C07D401/14
Filed: 2013-06-07
Abstract: The present invention provides compounds of formula I and compositions thereof which are useful as inhibitors of Bruton’s tyrosine kinase and which exhibit desirable characteristics for the same, wherein each R1 is independently hydrogen, an optionally substituted C1-6 aliphatic group, an optionally substituted 3-7 membered monocyclic heterocyclic group, or an optionally substituted heterocyclylalkyl group having 3-7 carbon atoms and 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R1 groups are taken together with their intervening atoms to form an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Ring A is wherein R2 is -Cl or –F; and R3 is –CF3, -OCF3, or –F.
Patent NZ-712592-A (NZ)
Title: Inflatable air mattress snoring detection and response
Inventor: TILSTRA MATTHEW WAYNE
IPC: A61B5/11
Filed: 2014-03-12
Abstract: A method can be provided that includes measuring pressure using a pressure sensor, determining, at a central controller of an air mattress system, one or more parameter values of the pressure, comparing the one or more parameter values with values, ranges, or patterns indicative of snoring, identifying a snoring state of a user, and initiating, with the central controller, a change to one or more adjustable features of the air mattress system.